INDIANAPOLIS, May 23, 2018 /PRNewswire/ --
Mahony will
continue in position through August
31, successor named at a later date
Eli Lilly and Company (NYSE: LLY) announced today that
Sue Mahony, Ph.D., senior vice
president of Lilly and president of Lilly Oncology, will retire at
the end of August after 18 years of service with the company.
Mahony is also a member of Lilly's executive committee.
(Logo:
https://mma.prnewswire.com/media/450388/Lilly_Logo.jpg )
"On behalf of our executive team and the company, I want to
thank Sue for her leadership over the past 18 years," said
David A. Ricks, Lilly's chairman and
chief executive officer. "Her passion for patients and strong sense
of purpose are inspiring to all of us."
Mahony led Lilly Oncology through the integration of ImClone,
successfully launched several key brands-including Verzenio™-and
most recently led the refocusing of the company's oncology R&D
strategy. Prior to this, as senior vice president of human
resources and diversity, Mahony played a key role in restructuring
the company into business units.
Mahony joined Lilly in 2000 after more than a decade in sales
and marketing roles in Europe for
Schering-Plough, Amgen and Bristol-Myers Squibb. At Lilly, Mahony
has held senior leadership positions in product development, Six
Sigma, marketing and general management roles.
"What I've appreciated over the years is the opportunity to
participate in something greater than myself," said Mahony. "We
make medicines that help patients with cancer live longer. What a
privilege it's been to wake up each morning with that as my life's
work."
Lilly is considering internal and external candidates to succeed
Mahony.
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with
discovery to make life better for people around the world. We were
founded more than a century ago by a man committed to creating
high-quality medicines that meet real needs, and today we remain
true to that mission in all our work. Across the globe, Lilly
employees work to discover and bring life-changing medicines to
those who need them, improve the understanding and management of
disease, and give back to communities through philanthropy and
volunteerism. To learn more about Lilly, please visit us at
www.lilly.com and www.lilly.com/newsroom/social-channels.
C-LLY
This press release
contains forward-looking statements about leadership changes within
Lilly's human pharmaceutical business and reflects Lilly's current
beliefs. There are risks and uncertainties related to leadership
changes, including with regard to identifying a successor to Ms.
Mahony and the timing of these changes. For discussion of important
risks and uncertainties, please see Lilly's latest Forms 10-Q and
10-K filed with the U.S. Securities and Exchange Commission. Lilly
undertakes no duty to update forward-looking statements.
Refer to: Kelley Murphy;
kmurphy@lilly.com ;
317-701-4007
This is a disclosure announcement from PR Newswire.